Xevinapant
Xevinapant was a tablet meant to make head and neck cancer cells easier to kill with chemoradiation by removing the proteins that stop them dying. A promising mid-stage trial was followed by a phase 3 that was stopped in 2024 because it was not working.
Overview
Xevinapant (Debio 1143) is an oral antagonist of the inhibitor-of-apoptosis proteins developed by Debiopharm and licensed to Merck KGaA in 2021. In a randomised phase 2 trial in locally advanced squamous cell carcinoma of the head and neck, adding it to cisplatin-based chemoradiation improved locoregional control and, on longer follow-up, survival, which made it the most anticipated radiosensitiser in the disease.
The confirmatory phase 3 TrilynX trial in unresected locally advanced disease was stopped for futility in 2024 after an interim analysis found it was unlikely to improve event-free survival, and the companion trial XRay Vision in resected high-risk disease was also halted; Merck KGaA returned the rights. The HPV-negative head and neck cancer page records it among the treatments that failed to improve chemoradiation.
- Linac head + MLC
- Target (PTV)
- Gantry arc
- Cone-beam CT guidance
Mimics the SMAC protein to block inhibitor-of-apoptosis proteins (XIAP, cIAP1 and cIAP2), restoring the cancer cell's ability to die after the DNA damage of radiotherapy and cisplatin.
1.Xevinapant slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Xevinapant" OR ABSTRACT:"Xevinapant" OR TITLE:"Debio 1143" OR ABSTRACT:"Debio 1143" OR TITLE:"AT-406" OR ABSTRACT:"AT-406" OR TITLE:"SM-406" OR ABSTRACT:"SM-406") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Xevinapant, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCelecoxib
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer) and the tag subtype-drugs-wave.
- TrialTrilynX
Shares Debiopharm, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer).
- TrialBonner trial (cetuximab plus radiotherapy)
Shares Radiosensitisers, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer).
- TrialACT II
Shares Radiosensitisers, Cisplatin.
- TrialRTOG 91-11
Shares Radiosensitisers, Cisplatin.
- TrialNIVOPOSTOP (GORTEC 2018-01)
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Cisplatin.
- TermExtranodal extension (ENE)
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Cisplatin.
- TrialOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Cisplatin.